Last reviewed · How we verify
Group S+P
Group S+P is a traditional Chinese medicine formulation that combines Salvia miltiorrhiza and Pueraria lobata to improve blood circulation and reduce inflammation.
Group S+P is a traditional Chinese medicine formulation that combines Salvia miltiorrhiza and Pueraria lobata to improve blood circulation and reduce inflammation. Used for Ischemic stroke or cerebrovascular disease, Angina pectoris, Myocardial infarction prevention.
At a glance
| Generic name | Group S+P |
|---|---|
| Sponsor | Huazhong University of Science and Technology |
| Drug class | Traditional Chinese medicine herbal combination |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
This herbal combination works through multiple pathways including vasodilation, antiplatelet effects, and anti-inflammatory mechanisms. Salvia miltiorrhiza (danshen) contains tanshinones that improve microcirculation, while Pueraria lobata (kudzu root) contains isoflavones with antioxidant and cardioprotective properties. Together they are used to enhance blood flow and reduce ischemic injury.
Approved indications
- Ischemic stroke or cerebrovascular disease
- Angina pectoris
- Myocardial infarction prevention
Common side effects
- Gastrointestinal upset
- Bleeding risk (minor)
- Allergic reactions
Key clinical trials
- Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer (PHASE3)
- Propofol Versus Sevoflurane Anesthesia on the Intraocular Pressure and Hemodynamics in Patient Undergoing Cyclophotocoagulation (NA)
- Bacteriophages in Addition to Antibiotics for the Treatment of Patients With Infective Endocarditis (PHASE3)
- Salivary Biomarkers for Concussion
- Effects of Serratus Anterior Plane Block (SAP), Pectoral Nerve Blocks (PECS I-II), and Standard Systemic Analgesia on Early Postoperative Recovery After Coronary Artery Bypass Grafting (NA)
- Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma (PHASE3)
- Empagliflozin and Anakinra for the Treatment of Postprandial Hypoglycemia in Patients With Prediabetes (PHASE2)
- Study of the Nutritional, Inflammatory, and Metabolic Endophenotypes of Attention-Deficit/Hyperactivity Disorder (ADHD) (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |